|Free Dividend Report|
|Stock Splits Calendar|
|AIMT Stock Split History|
|Preferred Stock Newsletter|
|AIMT Options Chain|
|Stock Message Boards|
Aimmune Therapeutics (AIMT) has 1 split in our AIMT split history database. The split for AIMT took place on November 17, 2004. This was a 5 for 1 split, meaning for each share of AIMT owned pre-split, the shareholder now owned 5 shares. For example, a 1000 share position pre-split, became a 5000 share position following the split.
When a company such as Aimmune Therapeutics splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business.
Looking at the AIMT split history from start to finish, an original position size of 1000 shares would have turned into 5000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Aimmune Therapeutics shares, starting with a $10,000 purchase of AIMT, presented on a split-history-adjusted basis factoring in the complete AIMT split history.
Growth of $10,000.00
Without Dividends Reinvested
|Average Annual Total Return:||-10.37%|
|About Aimmune Therapeutics|
|Aimmune Therapeutics is a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies. Co.'s main therapeutic approach, which it refers to as Characterized Oral Desensitized Immunology Therapy (CODIT), is designed to desensitize patients to food allergens and thereby reduce the risk of having an allergic reaction upon accidental exposure or reduce symptom severity should an allergic reaction occur. PALFORZIA (Peanut (Arachis hypogaea) Allergen Powder-dnfp) is Co.'s internally developed product utilizing CODIT and has been approved by the U.S. Food and Drug Administration and it is indicated for the mitigation of allergic reactions. According to our AIMT split history records, Aimmune Therapeutics has had 1 split.|
|AIMT Split History Table|
|11/17/2004||5 for 1|
|Healthcare Stock Splits|
|AIMT is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:
Also explore: AIMT shares outstanding history